The present status and problems of multi-target therapy of myasthenia gravis / 中华神经科杂志

ABSTRACT

The clinical manifestation of myasthenia gravis is due to the acetylcholine transmission defect of neuromuscular junction caused by autoimmune disturbance. With the intensive understanding of the pathogenesis and the emerging of specific immunological targeting therapy, therapeutic investigations are widely expanding. A multi-target therapy pattern is now available based on treatments primed to distinct immunopathological processes and improving neuromuscular junction transmission. We will comment the status and problems in this article.